| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Oregon’s 2020 measure legalizing psilocybin therapy within a regulated centers model is approaching actual implementation as the state’s health authority, the OHA, has begun granting licenses of different types.
So far, the OHA approved four facilitators and one lab, while worker permits mount to 81 and manufacturers to three, as of April 24.
The one license that has yet to be approved is that of service centers. Currently, a total of 17 applications have been filed for this category, and three are allegedly in the works of being approved — if they meet the requirements. Read more HERE.
Colorado’s approval of statewide natural psychedelics legalization along with the creation of legal treatment centers last November may soon become a reality.
The state Senate passed a bill addressing Proposition 122 on Tuesday, April 25. The measure was also greenlighted by the state’s House of Representatives after introducing additional amendments on Saturday 29.
“There are going to be additional things that we’re going to have to do to make sure we get it right. But a lot of people are watching," Senator Steve Fenberg, a Democrat, said at a hearing. "This is something that most states have not ventured to do. It’s important that we get it right.”
Read more on the bill’s proposals HERE.
In this new Psychedelics Exclusive podcast, The Dales Report founder Shadd Dales interviewed the CEO of Mind Medicine Inc. (NASDAQ:MNMD), Robert Barrow.
Nearly two years since his appointment as a top executive of the company, Robert gives his thoughts on the progress MindMed has made throughout his tenure. The psychedelic biotech industry is pushing the boundaries in the realm of mental health therapeutics, and Mr. Barrow reports that the company is receiving widespread acknowledgment for the accomplishments it is making. Read more HERE.
Canada-based mushrooms producer Red Light Holland Corp. (OTC:TRUFF) has launched a collaboration with former adult film performer and social media star Mia Khalifa.
The agreement comes less than a year after Red Light partnered Wiz Khalifa (no relation to Mia) to launch the MisterCap wellness line.
Mia, whose real name is Sarah Joe Chamoun, will lead the company's corporate social purpose strategy related to social justice, advocacy, the responsible use of magic truffles and the creation of a female-focused mushroom brand for health and wellness. Learn more HERE.
Mindset Pharma (OTC:MSSTF) has filed two international patent applications for its novel non-hallucinogenic compounds.
Incannex Healthcare (NASDAQ:IXHL) has contracted PharmAla Biotech to supply clinical-grade MDMA and psilocybin for new clinical trials.
Mydecine (OTC:MYCOF) is advancing a new set of MDMA analogs to the clinical stage.
Tryp Therapeutics (OTC:TRYPF) has closed an oversubscribed private placement for $1.6 million to advance its R&D program.
Awakn Life Sciences (OTC:AWKNF) has reported its quarterly and yearly financials.
Reunion Neuroscience (NASDAQ:REUN) has entered a compliance period for it currently does not meet NASDAQ’s listings requirements.
Red Light Holland and NUBU Pharmaceutical published a report toward educating lawmakers and physicians in Australasia on the potential benefits of microdosing psilocybin.
UK’s University of Exeter is offering a postgraduate program on psychedelics, while Mind Medicine Australia together with Dr. Ben Sessa hosted a free webinar on patient selection and integration.
Benzinga’s Cannabis Insider episode hosted a talk with the CEO of Bienstar Wellness, the Latin American clinic providing ibogaine therapy for the treatment of addictions.
Learn what the psychedelics discussion is looking like these days in Europe and the UK.
Check out PSYC Corp.’s new video series highlighting the integration of psychedelics into everyday life, some thoughts on how AI and psychedelics might collaborate and drugs through Batman’s Gotham lenses.
See Also: Last Week's Edition Of 'Psyched'
AdvisorShares Psychedelics ETF (NYSE:PSIL) opened Monday, May 1 at $1.71 and the whole week saw a downward trend considering the prior week’s range between $1.88 and $1.82. For this ETF, the yearly price range is set between $4.35 and $1.65.
Here's some EXCLUSIVE coverage from the event’s second edition:
MDMA Therapy Experts Debate Upcoming Approval, Psychedelic Market Opps
Ketamine Therapy Leaders Share Bold Vision For Future Of Psychedelics
In Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'
Fireside With Enveric Biosciences's Dr. Tucker, Unlocking Psychedelic Healing Benefits
Making The World A Better Place, How Psychedelics Are Helping
Posted In: AWKNF IXHL MNMD MSSTF MYCOF PSIL REUN TRUFF TRYPF
